Germline + tumour testing
Discuss both panel-based tests, including counselling and consent.
Home / GenomicsBetter-informed care.
PROSTATE CANCER · GENETICS & GENOMICS
Better-informed care.
For you and your family.
Compare the tests, follow the algorithm and understand the next step—all on this page.
Educational decision support, not an individual testing or treatment recommendation. Sources checked 19 September 2026.
01 · CHOOSE THE RIGHT TEST
Different questions.
Different tests.
| Test | Sample | Main question | What it can change |
|---|---|---|---|
| Germline genetic testing | Blood or saliva | Is there an inherited cancer-risk variant? | Personal risk assessment, family counselling and sometimes treatment. |
| Tumour / somatic profiling | Cancer tissue or circulating tumour DNA in blood | Does the cancer have a potentially actionable alteration? | Treatment or trial selection; some findings need separate germline confirmation. |
| Genomic risk classifier | Prostate tumour tissue | Can tumour biology refine a particular risk decision? | Selected surveillance or treatment discussions; not an inherited-risk test. |
Germline testing and tumour profiling complement each other. A blood sample alone does not tell you which test has been ordered.
02 · THE TESTING ALGORITHM
Follow the path from diagnosis.
For people diagnosed with prostate cancer. A cancer-free relative needs a separate genetics and screening assessment.
START
Confirmed prostate cancer
Review stage, grade, family history and previous genetic reports.
Has the cancer spread to distant sites?
Assess inherited-risk indications
High-risk disease, family history, known familial variant or suspicious tumour finding?
Indication present: arrange germline assessment.
No clear indication: discuss whether broader testing is appropriate; it is optional.
Assess clinical relevance
Consider treatment implications. If inherited, arrange genetics and family-risk care.
No action on VUS alone
Use clinical risk to guide care. Keep a route for reclassification updates.
Review the context
Continue standard care. Reassess limitations and further testing when clinically justified.
This is a discussion pathway, not an automated eligibility test. A result never replaces stage, grade, PSA or multidisciplinary assessment.
03 · FOR PATIENTS & FAMILIES
Your result. Your next step.
| Your report says | What it means | Your next step |
|---|---|---|
| Pathogenic / likely pathogenic | A clinically significant variant was found. Its meaning depends on the gene and whether it is inherited or tumour-only. | Review with your team. If inherited, discuss counselling and testing for relatives. |
| VUS: uncertain significance | The evidence is insufficient to classify the variant as harmful. This is not a positive result. | Do not change care on this finding alone. Ask how updates will reach you. |
| Negative | No relevant variant was detected by this test. It does not rule out every inherited risk or future treatment target. | Continue care based on your cancer and family history. |
| Failed / insufficient sample | The test could not produce a reliable answer. This is not a negative result. | Discuss another sample or another testing method. |
Before your visit
Bring your pathology report, previous genetic results and the cancer history of blood relatives on both sides of your family.
04 · CLINICIAN QUICK REFERENCE
Indication → assay → action.
| Clinical situation | Testing discussion | Action / interpretation |
|---|---|---|
| Metastatic prostate cancer | Germline panel plus somatic profiling | Offer both; absence of family history does not remove the indication. |
| High / very-high-risk or regional disease | Assess germline eligibility | Review pathology, family history and guideline criteria. |
| Known familial variant or suggestive cancer pedigree | Genetics referral / germline testing | Include both maternal and paternal relatives. Select the assay with genetics input. |
| Potential inherited finding on tumour testing | Confirmatory germline assessment | Do not infer inheritance from tumour sequencing alone. |
| Localised disease without a standard indication | Discuss broader germline testing if appropriate | Explain optional universal-testing approaches, costs and limitations; not a unanimous guideline requirement. |
| Selected localised risk decision | Consider a genomic classifier only if useful | Order when the result could change a defined decision; not routine for everyone. |
| Finding | Potential clinical relevance | What to check before acting |
|---|---|---|
| BRCA1 / BRCA2 alteration | May support a PARP-inhibitor strategy in an eligible advanced-disease setting. | Pathogenicity, exact drug indication, disease state, prior treatment and germline status. |
| Other HRR genes, e.g. ATM, PALB2, CHEK2 | Evidence and treatment eligibility differ by gene. | Do not assume every DNA-repair alteration predicts the same benefit as BRCA. |
| dMMR / MSI-high tumour | May support immunotherapy where indicated. | Confirm tumour biomarker and applicable approval; assess possible Lynch syndrome. |
| HOXB13 or other inherited susceptibility finding | May inform inherited-risk counselling. | A cancer-risk gene is not automatically a treatment target. |
| VUS in any gene | Not an actionable pathogenic finding. | No treatment or predictive family testing based solely on a VUS. |
HRR: homologous recombination repair. dMMR: deficient mismatch repair. MSI-high: high microsatellite instability. Check current Indian approvals, biomarker requirements, access and patient fitness before treatment selection.
Detailed explanations, counselling and India checklist
START WITH THE QUESTION
Three tests. Different answers.
Inherited risk
Germline testing usually uses blood or saliva to look for inherited variants. A finding can matter to relatives as well as to the person with cancer.
Treatment options
Somatic testing examines cancer tissue or tumour DNA in blood. It may identify treatment targets. A tumour finding does not by itself establish an inherited condition.
Cancer behaviour
Genomic classifiers, such as Decipher, analyse tumour biology to refine risk in selected situations. These are different from hereditary cancer panels and do not replace stage, grade or PSA.
Before you agree to testing
Bring the right information
Bring your biopsy report, treatment summary, previous genetic reports and a family cancer history from both sides of the family. Record cancer types and ages at diagnosis.
Ask what the result could change
Discuss benefits, limitations, cost, privacy, unexpected findings and implications for relatives. Testing is a choice; ask for counselling before and after the test.
THE UNIVERSAL TESTING DISCUSSION
Understanding universal germline testing
The Open Medicine pathway proposes offering comprehensive germline testing to everyone diagnosed with prostate cancer, regardless of stage or family history. Patients can accept or decline; the conversation can be revisited later.
This is a universal-testing proposal. It is broader than several guideline-based eligibility pathways and should not be presented as a unanimous guideline requirement.
Independent educational summary and original layout. No affiliation with, or endorsement by, Open Medicine is implied.
CLINICIAN PATHWAY
From indication to action.
Additional explanations for use alongside the charts above.
01 Establish the disease setting
Metastatic disease: ASCO recommends both germline and somatic panel testing. A normal family history does not remove this indication.
Non-metastatic disease: assess high/very-high-risk or regional disease, suggestive histology, family cancer patterns, a known familial variant and potentially inherited tumour findings. Criteria vary between guidelines.
No conventional indication: discuss a broader testing offer where appropriate, explaining the rationale, uncertainty and cost. Continue standard care if testing is declined.
02 Counsel, consent and select the assay
Document the testing purpose and informed consent. A hereditary panel commonly covers BRCA1/2, ATM, CHEK2, PALB2 and mismatch-repair genes; additional genes depend on the clinical context. Confirm the actual panel and methods rather than relying on a package name.
For tumour profiling, coordinate with pathology on suitable tissue. If prior testing was uninformative or the clinical state changes, consider repeat assessment with metastatic tissue or circulating tumour DNA.
03 Interpret the result category
Pathogenic / likely pathogenic
A clinically significant finding needs gene-specific interpretation. For an inherited finding, arrange genetics review and discuss targeted testing with at-risk relatives.
Variant of uncertain significance
A VUS is not a positive result. Do not use it alone to change treatment or direct predictive testing in relatives. Arrange a route for future reclassification updates.
Negative / uninformative
No relevant variant was detected by that test. This does not eliminate inherited risk or replace family-history assessment. Clarify sample and assay limitations.
04 Separate treatment decisions from family care
Treatment: integrate gene, variant, disease state and prior therapy. Appropriate findings may support PARP inhibitor strategies; prognostic-only sequencing findings should not direct treatment outside a trial.
MMR-related findings: assess tumour mismatch-repair / microsatellite-instability status and possible immunotherapy eligibility under the applicable indication. A Lynch syndrome diagnosis alone is not a treatment prescription.
Family care: arrange syndrome-specific counselling and screening. A BRCA alteration detected in the tumour warrants germline assessment; tumour and inherited testing are complementary.
Localised cancer: an inherited variant informs discussion but does not automatically dictate surgery or rule out surveillance. Review the whole clinical picture with the multidisciplinary team.
PUTTING THE PATHWAY INTO PRACTICE
A practical checklist for India
Before sending a sample
- Ask whether the laboratory’s accreditation scope covers the requested molecular test.
- Obtain a written quote: panel, sample transport, counselling and repeat-sample charges.
- Agree who will obtain the tissue block and confirm adequacy.
- Confirm turnaround time, report access and data-sharing consent.
Before acting on a result
- Book a results consultation, including genetics expertise when needed.
- Check current Indian drug approvals, the precise biomarker indication, affordability and trial access.
- Give the patient a copy of the report and a written next-step plan.
- Agree who will coordinate family counselling and future variant updates.
Practical implementation checklist for this site; not an Indian national guideline. Test availability and costs must be confirmed locally.
Questions worth asking
Does a genetic finding mean my family will get cancer?
No. An inherited risk variant can increase susceptibility; it does not predict that every relative will develop cancer. Relatives need their own counselling and, where appropriate, testing.
Will testing definitely find a new treatment?
No. A test may find no useful target, or a matched treatment may be unavailable or unsuitable. Biomarkers are one part of treatment selection.
Is a blood-based liquid biopsy the same as inherited testing?
No. The sample can be blood in both cases, but the laboratory analyses different material for different purposes. Check whether the order is for germline testing or tumour profiling.
Sources & further reading
- Open Medicine: Universal Germline Genetic Testing in Prostate Cancer — source pathway, published 5 September 2026.
- Yu et al. ASCO guideline: germline and somatic genomic testing in metastatic prostate cancer (2025)
- NCI: Genetics of Prostate Cancer (PDQ), professional version
- EAU Prostate Cancer Guidelines: diagnostic evaluation
- NCI: genetic testing for inherited cancer risk
- NCI: biomarker testing for cancer treatment
- EAU Prostate Cancer Guidelines: treatment and biomarker-directed therapy
Guidelines evolve. Confirm the current recommendation, assay performance and local treatment indication before clinical use.
PLAN YOUR VISIT
Out-of-town and international patients
Patients travel from across India and more than 25 countries. Video consultations are available so your reports can be reviewed and a plan agreed before you travel. Max Noida is roughly 40 minutes from Delhi's international airport.
Journey times vary with traffic. Please confirm travel and appointment arrangements with the care team.PATIENT EXPERIENCES
What patients say
Read verified patient reviews on GoogleTAKE THE NEXT STEP
A clearer picture.
A plan for you.
Bring your questions, your reports and your priorities.
We’ll discuss the options together.
CONSULT DR SACHIN ARAKERE NATARAJ
Max Super Speciality Hospital
Sector 128, Noida, Uttar Pradesh
Call +91 76762 73920 ↗OPD: 10 AM – 4 PM, daily · Max Super Speciality Hospital, Sector 128, Noida
Request on WhatsApp ↗Book via Max Healthcare ↗ALSO CONSULT IN BENGALURU
The care team confirms appointment requests. For urgent symptoms, seek emergency care.Aster CMI Hospital
Bengaluru, Karnataka
Aster Whitefield Hospital
Bengaluru, Karnataka
For Bengaluru appointments, call +91 76762 73920 or choose a hospital above. Please confirm consultation dates and timings with the care team.